Judge is reviewing a motion to appoint a group of 12 lawyers involved in AngioDynamics port catheter lawsuits to serve in various leadership positions, which will be discussed at a status conference on December 19.
Presiding Judge Ohta is expected to appoint a group of AngioDynamics port catheter lawyers to leadership positions, and prepare a group of bellwether cases for early test trials over the next few years.
At least 20 AngioDynamics port catheter lawsuits have been filed throughout the federal court system, each involving similar problems where the port catheter fractured, became infected or caused other problems.
Woman indicates that information about the risk of fractures and blood clots from Bard PowerPorts was known by the manufacturer for years before she received the port catheter for chemotherapy treatments
Missouri woman indicates that the Bard PowerPort Clearvue failure rate is substantially higher than other port catheters, but information about the risk of complications was concealed by the manufacturer
People of color suffering a pulmonary embolism were more likely to die in hospitals than their white counterparts.
The Rinvoq lawsuit says AbbVie executives mislead investors by failing to disclose safety concerns affecting Xeljanz would also apply to Rinvoq.
Pfizer allegedly knew about the blood clot risks with Xeljanz, but misled patients and the medical community in order to maximize profits.
